Avalyn Pharma Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

AVLN$31.17+5.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Comprehensive Income (Loss)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands, except share and per share amounts) (Unaudited)

	Three Months EndedJune 30,		Six Months EndedJune 30,
	2026	2025	2026	2025
OPERATING EXPENSES:
Research and development	$24,729	$17,882	$47,618	$33,201
General and administrative	6,561	3,895	11,581	7,292
Total operating expenses	31,290	21,777	59,199	40,493
LOSS FROM OPERATIONS	(31,290)	(21,777)	(59,199)	(40,493)
OTHER INCOME (EXPENSE):
Interest income	2,696	1,627	3,821	2,875
Interest expense	(272)	-	(370)	-
Other income (expense)	(69)	(41)	(56)	(76)
Total other income	2,355	1,586	3,395	2,799
NET LOSS	$(28,935)	$(20,191)	$(55,804)	$(37,694)
COMPREHENSIVE LOSS:
Net loss	$(28,935)	$(20,191)	$(55,804)	$(37,694)
OTHER COMPREHENSIVE LOSS:
Unrealized gains (losses) on marketable securities	(107)	(34)	(229)	(122)
Total other comprehensive loss	(107)	(34)	(229)	(122)
TOTAL COMPREHENSIVE LOSS	$(29,042)	$(20,225)	$(56,033)	$(37,816)
Net loss per share of common stock, basic and diluted	$(0.98)	$(17.63)	$(3.60)	$(52.83)
Weighted-average number of common stock used in net loss per share, basic and diluted	29,650,660	1,145,309	15,519,187	713,450

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.